UK markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4600+0.0500 (+3.55%)
At close: 04:00PM EST
1.5000 +0.04 (+2.74%)
After hours: 07:35PM EST
Sign in to post a message.
  • t
    tackitt
    Of all the stock advice services I have used, I find (http://trademarketview.tech) to be one of the absolute best! Their advice is well researched, helpful, and up to date. I don’t know how I ever went about day trading without reading their newsletter first!
  • J
    Jay
    Does anyone with actual knowledge of the market have any idea why this stock continues to drop every day since summer. Regardless of any news it continues to spiral down. Any brokers out there can explain? Looking for insight from smart people with real knowledge. Thankyou
  • s
    shkspr
    Who trades and invest regularly on this board? Who needs professional analysis and ideas?
  • a
    alan
    see shakes! every thing has good to it ! it's making lemonade from a lemon ! 😂😂😂😂👍🤠
  • p
    peter
    just one way....down!!!! How can this be that this stock went up to 9 and now it is trading close to 1! So not even the breast cancer results are anymore considered!!!!

    And CEO still expects to get share price above 10!!!
  • a
    alan
    please let me know how you like the content !! 🤔🤔🤔🤔🤔👍🤠
  • j
    jon
    Endoxifen (do your own research on this drug as it has some amazing potential) - Phase 2 in Australia (window of opportunity) stopped early due to overwhelmingly positive results and the want to proceed in America. They’ve already had 2 meetings with FDA setting up the foundation for phase 3 and approval. Currently have Phase 2 study in Sweden (further studying Endoxifens effect on premenopausal, high breast density women) that will conclude in summer, although if you’ve followed ATOS for awhile, I believe we will be in if not extremely close to phase 3 in the US before then.

    This drug is already revolutionary but it would be even more so in terms of breast cancer and cancer in general. Not to mention Atossa has $0 debt and has a cash reserve of $142 million.

    Read up on them and do your own DD.
  • a
    alan
    petru. imo. I'm SURPRISED yahoo allows the. abuse. that the group of posters gets away with ! I might even say. there giving them enough leeway to create a problem for themselves ! IMO.
  • m
    moe
    Bought 500 shares at 1.50 average is at 4.70 good luck to all
  • H
    H
    Penny territory soon. Nasdaq delisting letter soon thereafter.
  • r
    robert
    $ALNA conversation
    everyone here has it figured out, guess that's why analyst put an $11 price target on it today, again $ocgn .18 to $18 and $atos .95 to $9.80 in 2021, let that reloxolaise data that's coming be good and we will see if it stays under a buck for long
  • a
    alan
    OK ! HERE IT IS ....,ANAM. CARA. BY. JOHN. I.DONOHUE. A BOOK OF. CELTIC. WISDOM
  • Z
    Zsolt
    why is the ATOS CEO appearing on an anti-vaxx radio show when his flagship company (Covid therapy in the pipeline) is bleeding value??
  • B
    Bill
    This was Piescoffer99's latest big buy. He is down 80% now. Hehehe
    Cenntro Electric Group Limited (NAKD)
    NasdaqCM - NasdaqCM Real Time Price. Currency in USD
    Add to watchlist
    Visitors trend2W10W9M
    Quote Lookup

    2.6800-0.7900 (-22.7666%)
  • s
    swayngim
    They had some interesting insights about ATOS on http://trademarketview.tech. Definitely made me think twice about the company.
  • s
    subash
    Started going up
  • Z
    Zach
    How did this drop from $9 to $1.50 without any bad news. I mean seriously
  • B
    Bill
    Piescoffer99 getting his margin call! Hehehehehe

    https://media.tenor.com/videos/a65911e285d8fb39ac14dde8ed90c2d8/mp4
  • H
    Hunter
    EMPERY ASSET MANAGEMENT, LP 13G filling today. Rebound begins.
  • L
    Lukas
    Clinical trial - Phase 2 - NCT05068388 - Dose-Response Study of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density - is still recruiting.

    The raw study will take 6 months from date when recruting is completed.

    Estimated Primary Completion Date : July 28, 2023
    Estimated Study Completion Date : December 31, 2024

    Only two doses are being studied 1mg and 2mg. The cash reserve is not enough for such a long time, and certainly not when it turns out that phase 2 will need to be repeated with different dose.

    AT-301 Nasal Spray in Healthy Adults studied the drug and not a device, as far as I understand it. This is the reason why we have not heard for such a long time any news about inhal product. It is not easy to develope, certify and deliver medical device and drug for a small company. Moreover, it is not cheap and Atoss does not have money for this for now.

    Patent applications - portfolio:
    WO2019126538 - INTRADUCTAL METHODS OF TREATMENT OF BREAST DISORDERS - Seems to be not valid
    WO2019051368 - TOPICAL COMPOSITIONS - Not inventive
    WO2019051416 - METHODS FOR MAKING AND USING ENDOXIFEN - Not new/ Not inventive
    WO2021003433 - SUSTAINED RELEASE COMPOSITIONS OF ENDOXIFEN - Recently published

    covid-19 indications
    WO2021211808 - COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS - Not new/ Not Inventive
    WO2021194890 - HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS - Not new/Not inventive

    The patent application situation may change in the national phase and maybe some of them or all of them will be granted, but the question is, with which scope of protection and if their do worth it at the end. If the report from Patent Authorities like WIPO and EPO is so negative it will usually take a long time (up to 7 years in EU) and tons of money to obtaing patent granted. And without patent granted is hard to convince investors to invest :).

    Best you can do is to forgot about your money invested in Atossa and maybe one day you will be surprised :)